Health Care & Life Sciences » Medical Equipment & Supplies | Cytosorbents Corp.

Cytosorbents Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,422.70
4,122.80
4,791.60
9,527.80
15,150.80
22,503.90
Cost of Goods Sold (COGS) incl. D&A
1,911.60
2,133.90
2,212.50
3,953.70
5,518.40
7,489.40
Gross Income
511.10
1,988.90
2,579.10
5,574.10
9,632.40
15,014.50
SG&A Expense
5,224.30
9,267.70
11,882.70
17,066.20
19,475.00
30,599.40
EBIT
4,713.20
7,278.80
9,303.70
-
9,842.60
15,584.90
Unusual Expense
-
2,118.50
1,345.30
-
-
-
Non Operating Income/Expense
-
-
507.30
358.10
1,454.10
784.80
Interest Expense
422.80
310.00
-
231.80
749.10
1,461
Pretax Income
5,136.10
9,707.30
8,456.30
12,082.00
9,137.50
17,830.70
Income Tax
458.30
385.60
324.60
318.60
676.70
619.50
Consolidated Net Income
4,677.80
9,321.70
8,131.70
11,763.50
8,460.80
17,211.20
Net Income
4,677.80
9,321.70
8,131.70
11,763.50
8,460.80
17,211.20
Net Income After Extraordinaries
4,677.80
9,321.70
8,131.70
11,763.50
8,460.80
17,211.20
Net Income Available to Common
7,073.30
18,588.30
8,131.70
11,763.50
8,796.50
17,211.20
EPS (Basic)
0.75
1.29
0.33
0.46
0.32
0.56
Basic Shares Outstanding
9,440.80
14,382.80
24,885.80
25,433.70
27,613.90
30,719.20
EPS (Diluted)
0.75
1.29
0.33
0.46
0.32
0.56
Diluted Shares Outstanding
9,440.80
14,382.80
24,885.80
25,433.70
27,613.90
30,719.20
EBITDA
4,648.90
7,213.20
9,190.70
11,330.50
9,624.30
15,194.40
Non-Operating Interest Income
-
-
9.30
-
-
-
Preferred Dividends
2,395.50
9,266.70
-
-
335.70
-

About Cytosorbents

View Profile
Address
7 Deer Park Drive
Monmouth Junction New Jersey 08852
United States
Employees -
Website http://cytosorbents.com
Updated 07/08/2019
CytoSorbents Corp. engages in the development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product, CytoSorb, is a extracorporeal cytokine filter and seeks to reduce cytokine storm that could otherwise cause massive inflammation, organ failure, and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.